C12Y 304/22036
Caspase-1 , i.e. interleukin-1-beta-convertase
Official title: Caspase-1 (3.4.22.36), i.e. interleukin-1-beta-convertase
C12Y304/22036 (Caspase-1 , i.e. interleukin-1-beta-convertase) appears on 14 US grants and 21 published applications in this corpus.
Search patents in C12Y- Granted patents
- 14
- Published applications
- 21
- Assignees
- 14
- Inventors
- 34
- Latest grant
- 5 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 2 |
| 2003 | 1 | 0 |
| 2004 | 1 | 2 |
| 2005 | 1 | 0 |
| 2006 | 0 | 1 |
| 2007 | 2 | 2 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 2 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 1 | 1 |
| 2023 | 1 | 4 |
| 2024 | 1 | 2 |
| 2025 | 2 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Treatment for diseases caused by RNA virus SARS-CoV-25 Aug 2025US 12,377,127 B2Amerimmune LLC
- Inducible caspases and methods for use15 Jul 2025US 12,358,966 B2Poseida Therapeutics, Inc.
- Method of screening inhibitor of caspase activity by lipopolysaccharide12 Mar 2024US 11,926,860 B2Korea Institute of Science and Technology
- Inducible caspases and methods for use8 Aug 2023US 11,718,656 B2Poseida Therapeutics, Inc.
- Inducible caspases and methods for use5 Jul 2022US 11,377,480 B2Poseida Therapeutics, Inc.
- Inducible caspases and methods for use1 Jan 2026US 2026/0001929 A1Poseida Therapeutics, Inc.
- Mesenchymal stem cell line17 Oct 2024US 2024/0344031 A1UniversitäT Basel
- Procaspase-cleaving proteases and uses thereof29 Aug 2024US 2024/0287491 A1President and Fellows of Harvard College
- Inducible caspases and methods for use2 Nov 2023US 2023/0348553 A1Poseida Therapeutics, Inc.
- Treatment for Diseases Caused by RNA Viruses26 Oct 2023US 2023/0338459 A1Amerimmune LLC
Most cited
By later US patents
- Feline IL-18 proteins5US 7,928,197 B2Heska Corporation · 2011
- AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors4US 9,644,215 B2The General Hospital Corporation · 2017
- Inducible caspases and methods for use2US 11,377,480 B2Poseida Therapeutics, Inc. · 2022
- Inducible caspases and methods for use1US 12,358,966 B2Poseida Therapeutics, Inc. · 2025
- Canine interleukin 18 polypeptide1US 6,600,020 B1Toray Industries, Inc. · 2003